Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NEC Clear all
Completed No phase listed Observational

RBC Irradiation, Anemia and Gut Injury

NCT02741648
View directory record Official record
Conditions
Anemia, Necrotizing Enterocolitis
Interventions
Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Days
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

NCT01326923
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 6, 2026, 5:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479
View directory record Official record
Conditions
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
Interventions
[212Pb]Pb-MP0712, [203Pb]Pb-MP0712
Drug · Other
Lead sponsor
Molecular Partners AG
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Atlanta, Georgia • Glen Burnie, Maryland • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Completed No phase listed Observational

Observational Study of Surgical Treatment of Necrotizing Enterocolotis

NCT01223261
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Enterocolitis, Necrotizing, Intestinal Perforation
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Weeks
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

Effects of Delayed Cord Clamping in Very Low Birth Weight Infants

NCT00840983
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Intraventricular Hemorrhage, Late Onset Neonatal Sepsis, Motor Skills Disorders
Interventions
delayed cord clamping
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Results available

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

NCT01954017
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
STP206, Control
Biological · Other
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
1 Day to 4 Days
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
Hartford, Connecticut • Sunrise, Florida • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus

NCT01958320
View directory record Official record
Conditions
Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation
Interventions
pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, NSAID
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Days to 14 Days
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • San Jose, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 6, 2026, 5:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

NCT03647163
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions
VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 6, 2026, 5:35 AM EDT
Terminated No phase listed Observational

Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants

NCT01062828
View directory record Official record
Conditions
Premature Newborn, Necrotizing Enterocolitis
Interventions
Citrulline samples
Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 6, 2026, 5:35 AM EDT
Not listed Phase 1Phase 2 Interventional

Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO

NCT02851472
View directory record Official record
Conditions
Anemia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
2 Weeks and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Springfield, Massachusetts • Stony Brook, New York • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 6, 2026, 5:35 AM EDT
Completed No phase listed Observational

Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis

NCT01735578
View directory record Official record
Conditions
Anemia of Prematurity, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 12 Weeks
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 6, 2026, 5:35 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy

NCT03376984
View directory record Official record
Conditions
Dental Pulp Diseases, Dental Pulp Necrosis, Nerve Root Pain Nec
Interventions
ND and AMOX modified Gutta Percha, Gutta Percha
Combination Product · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 6, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions
225Ac-ETN029, 111In-ETN029
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness Trial for Diagnosis of Necrotizing Enterocolitis

NCT05573113
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Bowel Ultrasound, Abdominal radiograph
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 1 Year
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 6, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

Study of Normal Intestinal Development and Disease in Premature and Term Neonates

NCT06681129
View directory record Official record
Conditions
NEC, Necrotizing Enterocolitis, Intestinal Disease, Human Development
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 2 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Interventions
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Active, not recruiting Phase 2 Interventional

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

NCT04701307
View directory record Official record
Conditions
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Dostarlimab, Niraparib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Withdrawn Phase 1 Interventional

Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC

NCT06547424
View directory record Official record
Conditions
Necrotizing Enterocolitis, Intestinal Ischemia
Interventions
Chondroitin sulfate
Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Hour to 6 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 6, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

NCT06889493
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Neuroendocrine Tumors
Interventions
Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

NCT02477423
View directory record Official record
Conditions
Premature Birth of Newborn, Enterocolitis, Necrotizing
Interventions
Ampicillin, Gentamicins, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 6 Hours
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants

NCT00005888
View directory record Official record
Conditions
Necrotizing Enterocolitis, Sepsis
Interventions
Fortified Pasteurized Donor Human Milk supplement, Preterm Formula supplement
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 96 Hours
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 5:35 AM EDT
Completed No phase listed Observational

Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology

NCT00315263
View directory record Official record
Conditions
Lung Disease, Brain Injury, Necrotizing Enterocolitis, Respiratory Failure
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Sep 6, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants

NCT04284280
View directory record Official record
Conditions
Poor Growth in Extremely Preterm Infants, Necrotizing Enterocolitis
Interventions
Routine vs Selective use of Human Milk Donor Fortifier
Dietary Supplement
Lead sponsor
Crouse Hospital
Other
Eligibility
0 Days to 6 Days
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 6, 2026, 5:35 AM EDT
Not listed No phase listed Observational

Infant Formula Feeding and Necrotizing Enterocolitis in Newborns

NCT05121753
View directory record Official record
Conditions
Necrotizing Enterocolitis, Necrotizing Enterocolitis of Newborn, Sepsis Newborn, Cows Milk Allergy
Interventions
Survey investigating Infant formula feeding in newborns
Dietary Supplement
Lead sponsor
Neuroganics LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 6, 2026, 5:35 AM EDT